Zhi Tong Cai Jing·2025-08-22 07:57Group 1: Core Insights - The prevalence of hypertension in China is significant, with an estimated 245 million individuals affected, making hypertension a major risk factor for cardiovascular diseases, which account for nearly 50% of deaths in the country [1] - Current hypertension treatment primarily relies on medication, but adherence is low globally, and the efficacy of antihypertensive drugs is limited for a large population of resistant and uncontrolled hypertension patients [1] - There is an urgent need for new treatment methods beyond medication that can provide long-term and stable blood pressure control [1] Group 2: Advantages of RDN Therapy - RDN (Renal Denervation) is a percutaneous intervention technique that reduces sympathetic nervous system activity by ablating renal artery nerves, leading to long-term blood pressure control [2] - RDN offers all-day blood pressure reduction, good adherence, and relatively low side effects due to its minimally invasive nature [2] - Clinical trials and long-term follow-up studies have confirmed the effectiveness and safety of RDN, with significant milestones achieved in November 2023 when ReCor Paradise and Medtronic Simplicity Spyral received FDA approval [2] Group 3: Current Development and Competitive Landscape of RDN - Multiple RDN products have been approved both domestically and internationally, with significant market potential expected [3] - Internationally, ReCor and Medtronic are leading with FDA approvals, while Boston Scientific has acquired SoniVie to enhance its RDN offerings [3] - In China, by August 2025, four RDN products are expected to be approved, all utilizing radiofrequency ablation, indicating a competitive landscape with opportunities for domestic manufacturers to differentiate through innovation [3]